FRM
CGEM icon

Fox Run Management’s Cullinan Oncology CGEM Stock Holding History

Fox Run Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,204
Closed -$219K – 940
2025
Q4 		$219K Buy
21,204
+5,676
+37% +$51.2K 0.03% 780
2025
Q3 		$92.1K Buy
+15,528
New +$114K 0.01% 864
2023
Q1 		– Sell
-10,412
Closed -$110K – 688
2022
Q4 		$110K Buy
+10,412
New +$126K 0.04% 558

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fox Run Management's CGEM Position: Q1 2026 in Review

Fox Run Management sold out of Cullinan Oncology (CGEM) in Q1 2026, closing a stake of 21,204 shares — an estimated $219K sold.

Fox Run Management first reported a position in CGEM in Q4 2022 and held it in 3 quarters. The position peaked at $219K in Q4 2025. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Fox Run Management reported no remaining Cullinan Oncology position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 21,204 Cullinan Oncology shares in Q1 2026, an estimated $219K.
  • Fox Run Management first reported a position in Cullinan Oncology in Q4 2022 and held it in 3 quarters.
  • Fox Run Management's Cullinan Oncology position peaked at $219K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.